3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
7
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Endometrial Neoplasms
11
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
4
Vulvar Neoplasms
3
Peritoneal Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cervical Cancer Stage IB1
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Anus Neoplasms
1
Anastomotic Leak
1
Interventions
pembrolizumab
18
Cyclophosphamide
9
fludarabine
8
Nivolumab
8
cemiplimab
5
Carboplatin
5
atezolizumab
4
Gemcitabine
4
Filgrastim
4
Drug Therapy
4
Docetaxel
4
Cisplatin
4
palbociclib
3
durvalumab
3
Paclitaxel
3
Interleukin-2
3
Bortezomib
3
fludarabine phosphate
2
epacadostat
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
aldesleukin
2
Tobacco Use Cessation Devices
2
Temozolomide
2
SS1(dsFv)PE38
2
Riluzole
2
Peripheral Blood Stem Cell Transplantation
2
Oncolytic Virotherapy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Indocyanine Green
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled